74 results about "Telangiectasia" patented technology

The invention belongs to the field of cosmetics, and in particular relates to a skin care preparation and a using method of the skin care preparation. The skin care preparation consists of rose essential oil, chamomile essential oil, parsley essential oil, cypress essential oil, lavender essential oil, rose hydrosol, chamomile hydrosol, polyhydric alcohol, D-panthenol, amide substances, amino acid and derivatives thereof, collagen, glucan and hyaluronic acid. The skin care preparation disclosed by the invention is used for processing angiotelectasis in the surface of skin, and for contracting distended blood capillaries with a mixture of the plant essential oil; meanwhile, the skin care preparation, due to the added skin nutritional ingredients, can be used for repairing skin epidermis, enhancing skin immunity of the part of red blood silk and improving nutrition supply capacity of the epidermis so as to radically inhibit angiotelectasis; and a cure rate is more than 80%.

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dube Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose. Furthermore, the complex of the present invention possesses exceptional stability as a redispersed solution allowing the development of liquid based formulation for transdermal and other topical applications. The invention also relates to methods of formulating and manufacturing complex according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.